- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Elicera Therapeutics presents first clinical results from iTANK-armed CAR T-cell therapy at scientific conference | 1 | Cision News | ||
| 15.01. | ELICERA THERAPEUTICS: Elicera's candidate ELC-100 granted Orphan Drug Designation | 3 | Cision News | ||
| 13.01. | Elicera Therapeutics' drug candidate ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors | 2 | Cision News | ||
| 28.11.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 September 2024 | 55 | GlobeNewswire (Europe) | Third quarter (July-September 2024)
Operating profit/loss amounted to SEK -2,697,267 (-5,149,440).
Loss for the period amounted to SEK -2,514,629 (-5,046,574).
Cash flow from operating activities... ► Artikel lesen | |
| 27.11.24 | ELICERA THERAPEUTICS: Elicera's CEO: "ELC-100 stands apart from all other standard treatments" | 1 | Cision News | ||
| 12.11.24 | ELICERA THERAPEUTICS: Elicera's CEO: "One of the biggest milestones in our history" | 1 | Cision News | ||
| 05.11.24 | Elicera Therapeutics includes the first patient in the Phase I/II clinical study CARMA targeting B-cell lymphoma | 1 | Cision News | ||
| 04.11.24 | Elicera Therapeutics will present at the BioStock Life Science Summit, November 20 | 5 | Cision News | ||
| 24.10.24 | Elicera Therapeutics enrolls the last patient in the clinical phase I/II-trial with oncolytic virus ELC-100 | 3 | Cision News | ||
| 03.09.24 | Elicera Therapeutics will participate in upcoming industry and investor conferences during the fall | 2 | Cision News | ||
| 29.08.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2024 | 32 | GlobeNewswire (Europe) | Second quarter (April-June 2024)
Operating profit/loss amounted to SEK -5,841,409 (-4 466 286).
Loss for the period amounted to SEK -5,622,779 (-4,335,852).
Cash flow from operating activities... ► Artikel lesen | |
| 27.05.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2024 | 340 | GlobeNewswire (Europe) | First quarter (January-March 2024)
Operating profit/loss amounted to SEK - 5,433,422 (-2,265,857).
Loss for the period amounted to SEK - 5,369,677 (-2,266,329).
Cash flow from operating activities... ► Artikel lesen | |
| 14.05.24 | Nasdaq Stockholm AB: Change of Certified Adviser for Elicera Therapeutics AB | 229 | GlobeNewswire | As from May 15, 2024, Elicera Therapeutics AB (publ) will change Certified
Adviser to Mangold Fondkommission AB.
This information is distributed at the request of the Certified Adviser,
Carnegie... ► Artikel lesen | |
| 04.04.24 | Nasdaq Stockholm AB: New equity right for trading, Elicera Therapeutics AB TO2 | 291 | GlobeNewswire | At the request of Elicera Therapeutics AB, Elicera Therapeutics AB equity
rights will be traded on First North Growth Market as from April 5, 2024.
Security name: Elicera Therapeutics AB TO2
-------------------------------------------
Short... ► Artikel lesen | |
| 27.03.24 | Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTU) of Elicera Therapeutics AB | 279 | GlobeNewswire | Trading in Elicera Therapeutics AB paid subscription units is to cease. The
last trading day is March 28, 2024.
Short name: ELIC BTU
ISIN code: SE0021626306
Orderbook ID: 324876
This information... ► Artikel lesen | |
| 23.02.24 | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Elicera Therapeutics AB (91/24) | 584 | GlobeNewswire | With effect from February 26, 2024, the unit rights in Elicera Therapeutics AB
will be traded on First North Growth Market. Trading will continue up until and
including March 05, 2024.
Instrument:... ► Artikel lesen | |
| 19.02.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 19.02.2024 | 971 | Xetra Newsboard | Das Instrument CP6 US2166484020 COOPER COS INC. DL-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 19.02.2024 und ex Kapitalmassnahme am 20.02.2024 The instrument CP6 US2166484020 COOPER COS INC.... ► Artikel lesen | |
| 13.02.24 | Elicera Therapeutics AB: Year-End Report 1 January - 31 December 2023 | 222 | GlobeNewswire (Europe) | Fourth quarter (October-December 2023)
Operating profit/loss amounted to SEK -5,212,694 (-3,951,799).
Loss for the period amounted to SEK -4,749,222 (-3,898,340).
Cash flow from operating... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,165 | +3,22 % | Kampf um Unabhängigkeit: Evotec: Der Chef hat das Strategie-Update angekündigt | © Foto: Christian Charisius/dpa - dpa-BildfunkEvotec kämpft um seine Unabhängigkeit. Vorstandschef Christian Wojczewski setzt auf eine Strategieüberprüfung und will im April erste Ergebnisse präsentieren.... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 650,00 | -2,49 % | Looking Into Regeneron Pharmaceuticals' Recent Short Interest | ||
| BRAIN BIOTECH | 3,200 | +2,89 % | EQS-DD: BRAIN Biotech AG: Adriaan Moelker, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
16.01.2025 / 11:25... ► Artikel lesen | |
| SCORPIUS | 0,274 | +6,16 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer | DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,330 | +2,15 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research): Buy / Kursziel: USD 8,50 | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 22.11.2024 / 11:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,056 | -10,00 % | Burcon NutraScience Corporation: Burcon Launches Groundbreaking Sunflower Protein Isolate | Vancouver, British Columbia--(Newsfile Corp. - January 8, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| CSL | 162,46 | -0,48 % | The CSL share price is down 14% from its 52-week high. Is it a buy? | ||
| MANNKIND | 5,750 | +0,59 % | MannKind Reports Encouraging 6-month Data From Phase 3 INHALE-1 Study | WASHINGTON (dpa-AFX) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,672 | -3,13 % | Oxford Nanopore Technologies: Oxford Nanopore and UK Biobank to create world's first epigenetic dataset targeting the causes of cancer, dementia, complex disease | Pioneering research with potential to transform health outcomes through early detection, precise diagnoses, and personalised treatment for major diseases
Initiative will map the epigenome using... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,508 | -2,57 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to redefining the retina experience, today... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,565 | +1,80 % | Adaptimmune Therapeutics: Führungskraft veräußert Aktien im Wert von 3.243 US-Dollar | ||
| CODEXIS | 4,668 | -2,26 % | Codexis, Inc.: Codexis Announces New Employment Inducement Grants | REDWOOD CITY, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| TELO GENOMICS | 0,102 | -5,56 % | Telo Genomics mit SCHOCKIERENDER Prognose: Könnte der Kurs am Montag komplett einbrechen - Das dürfen Sie nicht verpassen! | ||
| BIORA THERAPEUTICS | 1,260 | 0,00 % | Biora Therapeutics, Inc.: Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth | Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora... ► Artikel lesen | |
| CORMEDIX | 11,800 | 0,00 % | CorMedix (NASDAQ:CRMD) Shares Down 4.2% - Should You Sell? |
Das Unternehmen ELICERA THERAPEUTICS AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,86 % bei einem Aktienkurs von 0,216 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.
